Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.

A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...

Vertex Pharmaceuticals (VRTX) is up more than +4% after receiving FDA approval for its non-opioid analgesic Journavx to treat moderate-to-severe acute pain in adults. LPL Financial Holdings (LPLA) is ...